Baxdrostat
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Baxdrostat
- Molecular weight
- 363.46
- Structure (SMILES)
- CCC(=O)N[C@@H]1CCCc2c(-c3ccc4c(c3)CCC(=O)N4C)cncc21
- baxdrostat
- Baxdrostat
- baxdrostat (formerly CIN-107) oral solution
- baxdrostat [INN]
- BAXDROSTAT [USAN]
- Baxdrostat [WHO-DD]
- baxdrostat 2mg
- baxdrostat inn
- baxdrostat usan
- baxdrostat who dd
- baxfendy
- BAXFENDY
- cin 107
- Cin-107
- CIN-107
- ro 6836191
- RO-6836191
- ro6836191
- Ro6836191
- RO6836191
- ATC classification codes
- C02KN02
Sources for recorded values
- CAS registry numbers
- 1428652-17-8
- ChEMBL ID
- CHEMBL4113975
- InChIKey
- VDEUDSRUMNAXJG-LJQANCHMSA-N
- PubChem compound IDs
- 71535962
- RxNorm IDs (RxCUI)
- 2743398
- FDA ingredient codes (UNII)
- NF3P9Z8J5Y
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- baxdrostat
- Type
- Synthetic organic
- Drug name stem
- -stat
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP11B2
- Gene symbol
- CYP11B2
- Protein identifier
- P19099
- Median affinity
- 7.89
- Affinity units
- pKi
- Condition
- Hypertension
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Atherosclerosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003914
- Subject identifier
- D050197
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003914
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004285
- Highest recorded phase
- 2
- Condition identifier
- EFO_1002006
- Highest recorded phase
- 2
- Condition identifier
- HP_0000822
- Highest recorded phase
- 3
- Condition identifier
- HP_0011736
- Highest recorded phase
- 3
- Condition identifier
- HP_0430034
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001422
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 3
- NCT01995383
- NCT04519658
- NCT05137002
- NCT05459688
- NCT05470725
- NCT05500820
- NCT05526690
- NCT05961384
- NCT05961397
- NCT05966324
- NCT06336356
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 62.3
- Calculated partition coefficient (ALogP)
- 3.56
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 27
- Molecular formula
- C22H25N3O2
- Monoisotopic mass
- 363.19467705
- Natural product
- No
- 0310-6001
- 0310-6002
- Recorded assays
- 2
- Active assays
- 2
Active assay types
- Confirmatory
Related records
Trials (27)
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
- A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.
- A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.
- A Study of CIN-107 in Adults With Primary Aldosteronism
- A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
- A Study of CIN-107 in Patients With Uncontrolled Hypertension
- A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
- A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
- A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
- A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
- A Study to Investigate the Effect on QTcF of Baxdrostat Compared With Placebo, Using Moxifloxacin as a Positive Control, in Healthy Participants
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
- A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants
- A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential
- Baxdrostat and Ventricular Remodeling
- Baxdrostat Bioavailability and Bioequivalence Study
- Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
In development for (3)
- Atherosclerosis Phase 1
- Heart failure Phase 3
- Hypertensive disorder Phase 2